Nilotinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Nilotinib?
Summarize this article for a 10 year old
Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome.[4] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.[4][5] It is taken by mouth.[5]
Clinical data | |
---|---|
Trade names | Tasigna, others |
Other names | AMN107 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608002 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30%[3] |
Protein binding | 98%[3] |
Metabolism | Liver (mostly CYP3A4-mediated)[3] |
Elimination half-life | 15-17 hours[3] |
Excretion | Faeces (93%)[3] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.166.395 |
Chemical and physical data | |
Formula | C28H22F3N7O |
Molar mass | 529.527 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Common side effects may include low platelets, low white blood cells, anemia, rashes, vomiting, diarrhea, and joint pains.[5] Other serious side effects may include QT prolongation, sudden death, pancreatitis, and liver problems.[5] It is not safe for use during pregnancy.[5] Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell.[5]
Nilotinib was approved for medical use in the United States in 2007.[5] It is on the World Health Organization's List of Essential Medicines.[6] It is approved as a generic medication.[7]